Satellite 2 – Beigene: Next generation BTK inhibitors: what’s in it for our Waldenström patients?
Presenters: Ann Janssens, Zachary Hunter, Jens Neefs, Vanessa Van Hende -
Feb 4, 2023
Chair: Ann Janssens
-Genomic landscape of Waldenström’s macroglobulinemia and impact on treatment?
Zachary Hunter, Dana Farber Cancer Institute, Boston, USA
-Pharmacokinetics of current BTKI and value for the clinic.
Jens Neefs, UZ Leuven, Belgium
-New Belgian guidelines
Vanessa Van Hende, VITAZ, Belgium